The use of artificial intelligence software in breast screening (Transpara®) makes it possible to identify studies with a very low probability of cancer. The hypothesis raised in this work is that reading strategies based on artificial intelligence (single or double reading only of cases with a score\> 7 with Transpara®), allow reducing the workload of a screening program by more than 50 % with respect to the standard reading of the program (double reading of all cases without Transpara®), without presenting inferiority in terms of detection rates and recalls of the program, both with the use of 2D digital mammography and with the use of tomosynthesis or 3D mammogram.
Age range
50 Years – 71 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Assessment of Workload of each strategy
Timeframe: In the middle of the study, at 1 year.
Assessment of Workload of each strategy
Timeframe: At the end of the study, at 2 years.
Detection rate
Timeframe: In the middle of the study, at 1 year.
Detection rate
Timeframe: At the end of the study, at 2 years.
Recall or referral rate
Timeframe: In the middle of the study, at 1 year.
Recall or referral rate
Timeframe: At the end of the study, at 2 years.